Influences on Female Adolescents’ Decisions Regarding Testing for Carrier Status of XSCID

Related Clinical Trial
cliniMACs HUD for T Cell Depletion Cord Blood Stem Cell Transplantation Study (COBLT) Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products Lentiviral Gene Therapy for Adenosine Deaminase (ADA) Deficiency Genetic Basis of Immunodeficiency IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency Sirolimus Prophylaxis for aGVHD in TME SCID Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft Influences on Female Adolescents’ Decisions Regarding Testing for Carrier Status of XSCID Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant EZN-2279 in Patients With ADA-SCID AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID) Patients Treated for SCID (1968-Present) Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China Gene Therapy for ADA-SCID MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim Natural History Study of SCID Disorders Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency SCID Bu/Flu/ATG Study With T Cell Depletion Generalized Neonatal Screening of Severe Combined Immunodeficiencies Neonatal Screening of Severe Combined Immunodeficiencies Gene Therapy for X-linked Severe Combined Immunodeficiency An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Registry Study of Revcovi Treatment in Patients With ADA-SCID Multi-center Clinical Study of Cord Blood Stem Cell Transplantation for SCID

Brief Title

Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID

Official Title

Decisions of Female Adolescents About Carrier Testing in Families With X-Linked Severe Combined Immunodeficiency (XSCID)

Brief Summary

      The purpose of this study is to learn what factors influence adolescent girls' decisions
      regarding testing for carrier status of X-Linked Severe Combined Immunodeficiency (XSCID). It
      will provide information about how healthy relatives feel about whether they could be XSCID
      carriers, whether carrier testing should be pursued, and, if so, at what age. Commonly known
      as "Bubble Boy Disease," XSCID is a rare, life-threatening immune system disorder that
      affects only males, but females who carry the gene mutation can pass the disease to their
      male children.

      Adolescent girls 13 to 17 years old who have a relative with XSCID and are known to be at
      risk for being carriers are eligible for this study.

      Participants will receive genetic counseling to help them decide if they want to be tested
      for the XSCID gene. Those who elect to be tested will provide a DNA sample from either a
      blood draw or brushing taken from inside the mouth. They will receive the test results from
      the same genetic counselor they spoke with before the testing.

      All participants will also talk with a psychologist over the phone once a year for 3 years to
      answer questions about how they are feeling and what they know about XSCID. They will be
      asked to discuss their decision and feelings about carrier testing.
    

Detailed Description

      This protocol studies carrier testing decisions of female adolescents who have a male
      relative with X-linked severe combined immunodeficiency (XSCID). XSCID is a rare
      immunodeficiency that affects only males, although females carrying XSCID mutations can pass
      the disease to their male offspring. In previous generations infant boys with XSCID uniformly
      died, but medical interventions such as bone marrow transplantation and now gene therapy,
      have proven life-saving for many patients. XSCID was mapped in 1987, and the disease gene was
      identified in 1993; these advances made possible patient and carrier diagnosis, which have
      been available on a research basis for 10 years through IRB-approved protocols of Dr. Puck. A
      large sample of XSCID families enrolling in molecular diagnosis protocols participated in her
      psychological study of the impact on adult siblings of having a brother affected with XSCID
      (Protocol OH98-HG-N015, Perception of Carrier Status in Families with X-Linked Severe
      Combined Immunodeficiency, now complete and terminated). That study indicated strong interest
      on the part of at-risk females for carrier diagnosis before reaching the age of adulthood.
      The current protocol is a follow-up protocol that functions in concert with Protocol
      95-HG-0066 (Genetic Analysis of Immune Disorders) to study the decision-making process and
      the impact of carrier testing in female adolescents from families with known XSCID mutations.
      With parental consent, carrier testing for girls from age 13 through age 17 will be discussed
      in a genetic counseling session. The 50% risk of being a carrier and the 50% chance of XSCID
      in male offspring of carriers will be explained. Possible psychological and other benefits
      and harms of testing will be aired. If elected by the girl, XSCID mutation testing will be
      performed by having her enroll in our genetic testing protocol 95-HG-0066. Follow-up
      interviews with all girls enrolled, both tested and not tested, will be conducted at 3 months
      and a year post encounter.
    


Study Type

Observational




Condition

Severe Combined Immunodeficiency



Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

40

Start Date

September 26, 2000


Primary Completion Date

September 25, 2008

Eligibility Criteria

        -  INCLUSION CRITERIA:

        Only families who have solicited adolescent carrier testing will be considered.

        Mentally competent females from 13 through 17 years of age are eligible to enroll if they
        have had a relative with XSCID proven by consistent medical history and mutation detection
        in IL2RG.

        Enrollees must be able to communicate in English (if a Spanish-speaking interviewer with
        appropriate expertise in genetics and psychology is located, interview forms may be
        translated so that subjects who speak Spanish can be included).

        All ethnic groups are eligible.
      

Gender

Female

Ages

13 Years - 17 Years

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00006335

Organization ID

000223

Secondary IDs

00-HG-0223


Study Sponsor

National Human Genome Research Institute (NHGRI)


Study Sponsor

, , 


Verification Date

September 23, 2009